Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection

Impact · against what's priced in

Lyell Immunopharma presents a potential valuation re-rating based on upcoming PiNACLE trial data in 2H26 and a cash runway extending to 3Q27. The stock currently trades near its cash value, suggesting the market is largely discounting the pipeline's clinical potential.

LYEL+0.60

No priced-in read yet

In context

The company has a catalyst in the second half of 2026 with PiNACLE trial data for ronde-cel and possesses a cash runway through 3Q27, providing a buffer against immediate dilution.

Read from the article alone

• healthcare▲3%
• biotech▲<1%
• valuation
• LYEL
• car t
• clinical trials
• immunotherapy
• pipeline